
A new study from Novo Nordisk supports the company’s launch of diabetes drug, Tresiba, a new basal insulin for once-daily use to treat type 1 and 2 diabetes. The drug is approved in many parts of the world, but not on the important US market.
The new study, which was presented at the European Association for the Study of Diabetes’ conference in Barcelona, shows that Tresiba has an effect even after 2.5 years.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app